If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
== Biochemistry == A1 receptors are implicated in sleep promotion by inhibiting wake-promoting cholinergic neurons in the basal forebrain. A1 receptors are also present in smooth muscle throughout the vascular system. In humans, the adenosine A1 receptor has been found to be most highly expressed in the brain, with lower expression in other tissues such as the testis, pancreas, and heart.
The KRRC Rhodesians were in the forefront of the Allied column pursuing the retreating Axis forces after El Alamein, advancing through Tobruk, Gazala and Benghazi before reaching El Agheila on 24 November 1942. They patrolled around the Axis right flank until being withdrawn to Timimi in December. Tripoli fell to the Eighth Army on 23 January 1943, and six days later Allied forces reached Tunisia's south-eastern frontier, where Italian and German forces manned the Mareth Line, a series of fortifications built by the French in the 1930s.
The chordae tendineae (sing.: chorda tendinea) or tendinous cords, colloquially known as the heart strings, are inelastic cords of fibrous connective tissue that connect the papillary muscles to the tricuspid valve and the mitral valve in the heart.
She said that TheJosh would have to schedule their workouts in two-week chunks, as a week is seven days, supposedly from Monday to Sunday. The Britannica Dictionary writes that a week is usually defined as Sunday to Saturday in American English, and Monday to Sunday in British English. TheJosh's account stated they were from the U.S., while Justin27's location was not listed.
-based regularization in a wavelet or other domain), such as via Ulf Grenander's Sieve estimator or via Bayes penalty methods or via I.J. Good's roughness method may yield superior performance to expectation-maximization-based methods which involve a Poisson likelihood function but do not involve such a prior. Attenuation correction: Attenuation occurs when photons emitted by the radiotracer inside the body are absorbed by intervening tissue between the detector and the emission of the photon. As different LORs must traverse different thicknesses of tissue, the photons are attenuated differentially. The result is that structures deep in the body are reconstructed as having falsely low tracer uptake. This must be corrected for when using quantitative PET imaging. One option for estimating attenuation coefficients is via a transmission scan, using a 68Ge rod source that is rotated around the patient Transmission scans directly measure attenuation values at 511 keV. With PET-CT scanners the 511 keV photon attenuation coefficients can be estimated using the Hounsfield units from the CT scan. Attenuation correction in PET-MRI scanners is more challenging, as the MRI images do not directly contain information on about the tissue attenuation coefficients, and the scanner bores are too narrow for a transmission scan.
Sources: en.wikipedia.org
== Eye disease == Mutation in rhodopsin kinase can result in diseases such as Oguchi disease and retinal degeneration. Oguchi disease is a form of congenital stationary night blindness (CSNB). Congenital stationary night blindness is caused by the inability to send a signal from outer retina to the inner retina by signaling molecules. Oguchi disease is a genetic disorder so an individual can be inherited from his or her parents. Genes that are responsible for Oguchi disease are SAG (which encodes arrestin) and GRK1 genes. Rhodopsin kinase is encoded from the GRK1 gene, so a mutation in GRK1 can result in Oguchi disease. Retinal degeneration is a form of the retinal disease caused by the death of photoreceptor cells that present in the back of the eye, retina. Rhodopsin kinase directly participates in the rhodopsin to activate the visual phototransduction. Studies have shown that lack of rhodopsin kinase will result in photoreceptor cell death. When photoreceptors cells die, they will be detached from the retina and result in retinal degeneration.
A Morpholino, also known as a phosphorodiamidate Morpholino oligomer (PMO), is a nucleic acid analog whose backbone consists of methylenemorpholine rings linked through phosphorodiamidate groups, in contrast to the sugars linked through phosphates found in natural nucleic acids. Synthetic oligomers of Morpholinos are used in molecular biology to modify gene expression. Morpholinos block access of other molecules to small (~25 base) specific sequences of the base-pairing surfaces of ribonucleic acid (RNA). Morpholinos are used as research tools for reverse genetics by knocking down gene function. Morpholinos are in development as pharmaceutical therapeutics targeted against pathogenic organisms such as bacteria or viruses and genetic diseases. A Morpholino-based drug eteplirsen from Sarepta Therapeutics received accelerated approval from the US Food and Drug Administration in September 2016 for the treatment of some mutations causing Duchenne muscular dystrophy, although the approval process was mired in controversy. Other Morpholino-based drugs golodirsen, viltolarsen, and casimersen (also for Duchenne muscular dystrophy) were approved by the FDA in 2019–2021. "Morpholino" is often capitalized to distinguish the nucleic acid type from other chemicals containing a six-membered morpholine ring, but this usage is not consistent across scientific literature. Vivo-Morpholinos and PPMO are modified forms of Morpholinos with chemical groups covalently attached to facilitate entry into cells.
The ILEA also ran a watersports centre at Greenland Dock in Bermondsey, and the Centre For Life Studies, a training centre for biologists in secondary education, at London Zoo; and funded the zoological collections Horniman Museum in Forest Hill, south London, and the Geffrye Museum, now the Museum of the Home, in Hoxton. The ILEA also had its own boarding school at Wolverstone Hall, near Ipswich in Suffolk.
=== Impacts of gender stereotypes in health and medicine === Gender stereotypes influence both diagnosis and treatment practices for men and women. Ancient theories, such as those of Hippocrates, perpetuated hierarchical models in which the female body was considered a deviation from the male norm—a view that persisted into the 19th century. Some diseases are underdiagnosed in one sex due to stereotypical associations. For instance, women are less frequently and less accurately diagnosed with myocardial infarction, despite an increase in incidence among women between 2008 and 2013 (+20%). Symptoms in women may differ from those in men and are less well-known or recognized. In 2015, cardiovascular disease accounted for 51% of deaths in women in Europe. Similar disparities exist in other conditions. Women with chronic obstructive pulmonary disease (COPD) are diagnosed later than men, even though prevalence is now similar. Women with autism spectrum disorders are often diagnosed late, which has been linked to significantly reduced life expectancy compared to non-autistic women. Strokes, more common among women, also have more severe outcomes in women but were less studied in female patients as of 2017. Conversely, some conditions such as osteoporosis are underdiagnosed in men, as the disease is often seen as predominantly affecting women. Despite this, men represent one-third of hip fractures and have a higher risk of complications.
The term "mutton" is applied to goat meat in most countries of South Asia, and the goat population has been rising. For example, mutton curry is usually made from goat meat. It is estimated that over a third of the goat population is slaughtered every year and sold as mutton. The domestic sheep population in India and the Indian subcontinent has been in decline for over 40 years and has survived at marginal levels in mountainous regions, based on wild-sheep breeds, and mainly for wool production. However, in some Indian states (such as karnataka, Andhra Pradesh, Tamil Nadu and Telangana), sheep meat is also popular.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.